Cardiac Changes in Early Parkinson’s Disease: A Follow up Study

Cardiac Changes in Early Parkinson’s Disease: A Follow up Study

Publication date: Jan 07, 2020

The purpose of this study is to investigate the long-term effects of treatment with the adrenergic blocker carvedilol on serial DaTscan, a dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging technique in a population of subjects with defined pre-motor Parkinson’s disease risks (i.e., REM sleep Behavior Disorder (RBD) and at least one among hyposmia, constipation, depression and color vision abnormality) and abnormal 123. I-Metaiodobenzylguanidine (MIBG) scintigraphy. Primary procedures in this study are MIBG scan, DAT scan, Neuromelanin Magnetic Resonance Imaging (NM-MRI), and carvedilol titration. Subjects will return for research visits and imaging every six months,for three years. We hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism. If this is true, it might create a considerable window of opportunity for treatment with adrenergic blockers – or similar compounds able to reduce Sympathetic Nervous System (SNS) hyperactivity – which may result in long-term benefits such as delaying the neurodegenerative process and the onset of neurological symptoms.

Concepts Keywords
Adrenergic MRI
Atrial Fibrillation Magnetic Resonance Imaging
Carvedilol Tomography
Color Vision Major depressive disorder
Computerized Tomography Organ systems
Constipation Iobenguane
COPD Carvedilol
DAT Medicine
Dementia Branches of biology
Depression Adrenergic antagonist
Dopamine Transporter Scottish inventions
Heart Failure Beta blockers
Hyperactivity Antihypertensive agents
Informed Consent RTT
Kidney Secondary Parkinsonism
LVEF Tardive Concurrent dementia
Magnetic Resonance Imaging
REM Sleep


Type Source Name
drug DRUGBANK Iobenguane
disease MESH depression
disease MESH REM sleep Behavior Disorder
drug DRUGBANK Dopamine
drug DRUGBANK Carvedilol
pathway KEGG Parkinson disease
disease MESH Parkinson Disease
disease MESH Sleep Apnea
disease MESH COPD
disease MESH Diabetes mellitus
disease MESH Atrial fibrillation
disease MESH Heart failure
disease MESH dementia
disease MESH Secondary Parkinsonism


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *